Medical breakthrough: Seattle man is first adult to get new gene therapy for vision

April 10, 2018 by Sandi Doughton, The Seattle Times

Toby Willis gave up on medical miracles long ago.

The Seattle man's eyesight started deteriorating when he was just a kid and couldn't figure out why he kept crashing into things. By the time he was in his early 40s, Willis' visual world had dimmed to shadows and silhouettes.

Still, he refused to obsess over scientific advances.

"I made it a point not to go down those rabbit holes, to be chasing that pipe dream," Willis said.

Nevertheless, the possibility that something might be on the horizon occasionally tickled at the back of his mind.

So Willis checked in with his eye doctor late last year, setting in motion a train of events that culminated March 20 at Children's Hospital Los Angeles (CHLA) when he became the first adult to undergo the first gene therapy approved in the U.S. for treatment of an inherited disease.

The medication, called Luxturna, is injected in the eye and uses a harmless virus to deliver working versions of a gene to the cells of patients whose own are defective. It targets a single, rare mutation, but has raised hopes that after decades of disaster and disappointment, a wave of for other disorders is on the way.

At the same time, Luxturna's staggering price tag of $425,000 per eye is raising questions about who can afford the newest medical technologies—and whether the results will justify the costs.

Willis already knows it won't be a miracle cure for him. The therapy is expected to work best in children diagnosed early, before disease causes irreversible damage to their eyes. In Willis' case, doctors hope it will keep the 44-year-old software engineer's eyesight from getting worse and—perhaps—improve his ability to distinguish objects and navigate the world.

"As much as I would love to have a full range of 20-20 vision, that's not realistic for me," Willis said. "But to be able to recognize my fiancee's face or see my , or maybe enjoy a more rich experience in my travels and hiking—that would be a big deal."

Without the surgery, Willis' disease would eventually extinguish his eyesight altogether.

For physicians who have helplessly watched patients like Willis go blind, even an imperfect treatment represents a breakthrough. For gene-therapy researchers, it's a thrilling validation.

"I think this is a game changer," said Timothy Cherry, who's exploring different ways to repair inherited forms of blindness at Seattle Children's Research Institute. "What I see as inspiring is that this shows us that the fundamental idea works."


Willis grew up in rural Tennessee, where he played and worked on his family's farm. By middle school he had to sit at the front of the class to see the board. Doctors diagnosed retinitis pigmentosa, a range of disorders that relentlessly erode the biological machinery of sight.

His mother, a nurse, launched her son on a crash course in Blindness 101: mastering Braille, learning to navigate blindfolded, practicing with a cane.

When Willis encountered job discrimination, he started his own industrial maintenance business.

"People were scared to hire me because my eyes didn't work perfectly," he said. "It forced me to be entrepreneurial and forge my own ways."

Seeking greater independence, a progressive community and better mass transit, he moved to Seattle in 2006 with his first guide dog at his side.

In his new home, Willis created a nonprofit called Independence Guide Dogs, to train animals and match them with owners. His long-standing fascination with computer technology and frustration with the roadblocks it presents to people with disabilities landed him a job at Expedia, where he works to make the online travel-booking site accessible to all.

The company's generous health benefits covered the cost of having both eyes treated with Luxturna. But first, Willis had to get tested in Seattle to find out if his vision loss was caused by a defective version of a gene called RPE65, which is vital for recycling molecules used to convert light into the electrical signals the brain processes into images.

The geneticist was giddy when she called to tell Willis he carried the mutation found in only about 1,000 to 2,000 Americans, knowing it meant he might benefit from the new therapy. The disorder caused by the mutation is called Leber congenital amaurosis, a more precise diagnosis than Willis got as a teen in Tennessee.

Just seven medical centers in the country are approved by Luxturna's developer, Spark Therapeutics, to deliver the treatment. Willis picked The Vision Center at CHLA, which offers the therapy to children and adults, and headed there as soon as possible.

"My doctor said, 'Time is retinal cells.' The longer I wait, the more I have to lose," he said.

His left-eye surgery came a few hours after 13-year-old Jack Hogan in Boston became the country's first Luxturna patient outside of . Willis' right eye was treated on March 27.


The procedure takes only about an hour, but the level of precision required is nerve-wracking, said CHLA Vision Center surgeon and researcher Dr. Aaron Nagiel. With a tiny light illuminating the inside of the eyeball, he had to thread a needle through an inserted port and inject a .3 milliliter drop of viral solution between the photosensitive rod-and-cone layer of the retina and an underlying layer, called the retinal pigment epithelium, where the RPE65 gene carries out its mission.

If something goes wrong, there's a single backup vial of the costly fluid.

Each injection contains about 150 billion viruses, which invade the target cells and deposit "good" genes into their nuclei.

In clinical trials, 27 out of 29 patients experienced improvements in eyesight that lasted at least a year, and more than 70 percent were able to navigate better in very low light. Some participants experienced dramatic revelations, like seeing the stars for the first time. One patient's vision got worse.

The treatment can trigger cataracts, but that's not a problem for Willis. Cataracts are common in people with his condition, possibly triggered by inflammation, so he already had his cloudy lenses replaced with clear, synthetic versions.

"In some ways I'm the perfect patient," he said. "I've lost enough vision that the risk-benefit ratio is much more tilted toward the benefit side."

The eye also presents a "perfect storm" of favorable conditions for the first gene-therapy success after nearly 30 years of failed attempts, Cherry said.

The entire field of research was nearly derailed in 1999, when a runaway immune response killed an 18-year-old man in a trial treatment for a liver disorder. In 2003, an for the immune deficiency called "bubble boy" syndrome activated cancer-causing genes and triggered leukemia in two children.

Immune response is muted in the eye, so there's little chance the gene-carrying virus will trigger rejection, Cherry explained. And because the virus used in Luxturna doesn't insert its genes directly into the host cell's chromosomes, the danger of switching on disease genes is low.

The eye is also a small target, which means a small drug dose. And decades of basic research on the causes of blindness laid a solid foundation for the breakthrough by identifying culprit genes and figuring out how they work.

Gene therapies for several other inherited diseases are already in the pipeline, including against sickle cell disease and a type of muscular dystrophy. Common eye disorders, like glaucoma, diabetic retinopathy and macular degeneration, will be tougher to tackle because they involve multiple genes as well as lifestyle factors, Cherry cautioned.

"We have high hopes that we can push on these sorts of technologies and deliver more treatments in the future, but it's important to be realistic," he said.

It's still wait and see

Days after his first treatment, Willis said he already noticed that his world seemed brighter, as if more light was getting through. Edges appeared a little crisper.

The full benefits won't be clear for another month, and Willis is trying to keep his hopes in check.

Even if all the treatment does is stop further deterioration, Willis says that would make it worthwhile to him.

"This is really the only treatment we have for this devastating, progressive form of blindness," Nagiel said.

But one of the biggest uncertainties is how long the benefits will last.

The latest data from Sparks Therapeutics, which hasn't yet been published, extends out three years.

The mother of a 5-year-old boy with the same genetic mutation recently discussed the treatment with Nagiel. Her main worry is that her son would be devastated if his eyesight cleared, only to be lost again after a few years.

"I had never thought of that," Nagiel said. "But it's a concern ... and we don't have the answers yet."

Explore further: Massachusetts Eye and Ear performs first FDA-approved gene therapy procedure for inherited disease

Related Stories

Massachusetts Eye and Ear performs first FDA-approved gene therapy procedure for inherited disease

March 20, 2018
Massachusetts Eye and Ear made medical history on Tuesday by performing the first post-FDA approval gene therapy for patients with a form of inherited blindness. The occasion marks the beginning of a new era in medicine, ...

Genetic treatment for blindness may soon be reality

November 11, 2017
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting ...

FDA panel mulls gene therapy for kids with rare eye disease (Update)

October 12, 2017
(HealthDay)—A U.S. Food and Drug Administration advisory panel was poised on Thursday to recommend approval for a gene therapy that could grant the gift of sight to young people with a rare type of inherited vision loss.

Gene therapy for rare form of blindness wins US approval

December 19, 2017
U.S. health officials on Tuesday approved the nation's first gene therapy for an inherited disease, a treatment that improves the sight of patients with a rare form of blindness. It marks another major advance for the emerging ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

Seeing hope: FDA panel considers gene therapy for blindness (Update)

October 9, 2017
A girl saw her mother's face for the first time. A boy tore through the aisles of Target, marveling at toys he never knew existed. A teen walked onto a stage and watched the stunned expressions of celebrity judges as he wowed ...

Recommended for you

Scientists cut main heart disease risk locus out of DNA by genome editing

December 6, 2018
Over the past decade we've learned that billions of people carry a mysterious specter in their DNA that strongly increases their risk for life threatening cardiovascular diseases, such as heart attacks, aneurysms or strokes, ...

What can a snowflake teach us about how cancer spreads in the body?

December 6, 2018
What can seashells, lightning and the coastline of Britain teach us about new drugs for cancer?

New genetic insight could help treat rare debilitating heart and lung condition

December 6, 2018
The largest study of genetic variation in patients with pulmonary arterial hypertension has associated two important genes with the disease.

Are scientists studying the wrong kind of mice?

December 5, 2018
Mice represent well over half of the non-human subjects of biomedical research, and the vast majority of those mice are inbred. Formed by generation after generation of mating between brothers and sisters, inbred mice are ...

Researchers find evidence of prenatal environment tuning genomic imprinting

December 5, 2018
A team of researchers from the U.S., Australia and Denmark has found evidence of the prenatal environment tuning genomic imprinting. In their paper published in Proceedings of the National Academy of Sciences, the group describes ...

Gene that lets you eat as much as you want holds promise against obesity

December 4, 2018
It sounds too good to be true, but a novel approach that might allow you to eat as much food as you want without gaining weight could be a reality in the near future.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.